Table 1.
Demographic and clinical characteristics of vaccinated HCWs without and with breakthrough infections
| Age (years) | Control Group∗ n = 34 46.3 (12.15) | Breakthrough Infections∗, ∗∗ n = 33 39.9 (11.3) |
|---|---|---|
| Sex | ||
| Female | 26 (77%) | 23 (70%) |
| Male | 8 (23%) | 10 (30%) |
| Hospitalization status | ||
| Never hospitalized | 34 (100%) | 33 (100%) |
| Hospitalized | n/a | 0 (0%) |
| Unknown if hospitalized | n/a | 0 (0%) |
| Sample Collection Date | December 2020-September 2021 | April 2021-September 2021 |
| SARS-CoV-2 PCR Positivity | ||
| Positive | 0 (0%) | 33 (100%) |
| Negative | 34 (100%) | 0 (0%) |
| Peak Disease Severity (Female [F], Male [M]) | ||
| Asymptomatic | n/a | 24 (73%) (16 [F], 8 [M]) |
| Mild (Non-hospitalized) | n/a | 9 (27%) (7 [F], 2 [M]) |
| Moderate (Hospitalized) | n/a | 0 (0%) |
| Severe (Hospitalized) | n/a | 0 (0%) |
| Unknown | n/a | 0 (0%) |
| SARS-CoV-2 clade∗∗∗ | ||
| Alpha | n/a | 4 (12%) |
| Gamma | n/a | 3 (14%) |
| Delta | n/a | 20 (61%) |
∗
analyzed before vaccination and 1 week, 3, 6, and 9 months after the second dose
∗∗
for 21, multiple samples were analyzed; from 12 cases, only one sample was available
∗∗∗
information available for 27 patients with a nasopharyngeal viral load sufficient for genome sequencing